Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 16/20 | 1.00 |
| ▸ | BCHE known ✓ | P06276 | 8/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CACNB4 | O00305 | 1/20 | 1.00 |
| ▸ | CACNA1A | O00555 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | CACNA1G | O43497 | 1/20 | 1.00 |
| ▸ | CACNG3 | O60359 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | CACNA1H | O95180 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | FABP1 | P07148 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tacrine SCHEMBL7714835 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL29681895 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL2828 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL9407893 | 0.98 | CYP1A2 (0.97) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL8000475 | 0.98 | ACHE (0.97) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL7638777 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| SCHEMBL12043403 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL3270 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL14236722 | 0.98 | ACHE (0.97) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL1044163 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043316-A1 | PROCESS FOR OBTAINING ANTI-INFLAMMATORY COMPOUNDS, SAID COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUNDS AND OF THE PHARMACEUTICAL COMPOSITION | UNIVERSIDADE ESTADUAL DE CAMPINAS (BR) | 2025-03-06 | — | — | WO | disclosed |
| EP-4304591-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR DEMENTIA | Heptares Therapeutics Limited (GB) | 2024-01-17 | — | — | EP | disclosed |
| CN-116981457-A | Low concentration doses of synergistic ophthalmic compositions effective in preventing, controlling and eradicating presbyopia | 塞萨尔·亚历杭德罗·桑切斯·加莱亚纳 | 2023-10-31 | — | — | CN | disclosed |
| CN-115124511-B | Tacrine derivatives, preparation method thereof and application of tacrine derivatives as CDK2/9 inhibitor | 中国人民解放军北部战区总医院 | 2023-09-26 | — | — | CN | disclosed |
| CN-114853672-B | Tacrine derivatives as CDKs inhibitors and uses thereof | 中国人民解放军北部战区总医院 | 2023-06-23 | — | — | CN | disclosed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4090969-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2022-11-23 | — | — | EP | disclosed |
| CN-115124511-A | Tacrine derivative, preparation method thereof and application of tacrine derivative as CDK2/9 inhibitor | 中国人民解放军北部战区总医院 | 2022-09-30 | — | — | CN | disclosed |
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CUREVAC AG (DE) | 2022-09-22 | — | — | US | disclosed |
| WO-2022189366-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR DEMENTIA | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-09-15 | — | — | WO | disclosed |
| CN-114853672-A | Tacrine derivatives as CDKs inhibitors and application thereof | 中国人民解放军北部战区总医院 | 2022-08-05 | — | — | CN | disclosed |
| EP-4013880-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CureVac AG (DE) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022111742-A1 | PHARMACEUTICAL COMPOSITION OF NAPHTHALENE DERIVATIVES AS MULTI-TARGET THERAPEUTIC AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | CENTRO DE NEUROCIENCIAS DE CUBA (CU) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022103250-A1 | SYNERGISTIC OPHTHALMOLOGICAL COMPOSITION IN A LOW-CONCENTRATION DOSE THAT IS EFFECTIVE IN THE PREVENTION, CONTROL AND ERADICATION OF PRESBYOPIA | SANCHEZ GALEANA CESAR ALEJANDRO (MX) | 2022-05-19 | — | — | WO | disclosed |
| CN-114502204-A | RNA combinations and compositions with reduced immunostimulatory properties | 库尔维科公司 | 2022-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | TLR3, EIF2AK2, STING1 | ACHE 4829/4885BCHE 4715/4885TSHR 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.